Related Experiment Video

Updated: Aug 24, 2026

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
12:42

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

Virosomes as new carrier system for cancer vaccines

Ruth Schwaninger1, Ernst Waelti, Paul Zajac

  • 1Department of Clinical Research, University of Bern, Bern, Switzerland.

Cancer Immunology, Immunotherapy : CII
|June 9, 2004
PubMed

Insights

Virosomes carrying HER-2/neu protein fragments generated potent anti-tumor immune responses in mice. This novel vaccine approach successfully rejected tumors and offers promise for human immunotherapy trials against HER-2/neu-positive cancers.

Area of Science:

  • Oncology
  • Immunology
  • Vaccine Development

Background:

  • HER-2/neu is a tumor-associated antigen overexpressed in many cancers, making it a key target for immunotherapy.
  • Previous protein vaccines targeting HER-2/neu have shown limited efficacy in preventing tumor growth.
  • Virosomes, safe and clinically approved vaccine carriers, can serve as adjuvants and delivery systems for tumor antigens.

Purpose of the Study:

  • To evaluate the immunogenicity and anti-tumor efficacy of HER-2/neu protein fragments (pNeuECD) delivered via virosomes.
  • To assess the potential of virosome-based vaccines for generating humoral and cell-mediated immune responses against HER-2/neu.
  • To provide preclinical data for designing human vaccination trials targeting HER-2/neu-overexpressing tumors.

Main Methods:

  • Mice were vaccinated with truncated HER-2/neu extracellular domain (pNeuECD) either encapsulated in or bound to virosomes (Vir-pNeuECD).
  • Humoral and cytotoxic immune responses against HER-2/neu were measured post-vaccination.
  • Tumor rejection and tumor formation were monitored in vaccinated mice challenged with HER-2/neu-expressing tumors.

Main Results:

  • Vir-pNeuECD vaccination induced significant HER-2/neu-specific humoral and cytotoxic immune responses.
  • Significant tumor rejection was observed in mice vaccinated with Vir-pNeuECD.
  • No difference in tumor rejection was noted between virosome-encapsulated and membrane-bound pNeuECD constructs.

Conclusions:

  • Virosomes are effective carriers and adjuvants for pNeuECD, eliciting robust anti-tumor immunity.
  • Virosome-based HER-2/neu vaccines demonstrate potential for inducing tumor rejection and can be explored for clinical applications.
  • This study provides crucial preclinical evidence supporting the development of virosome-based immunotherapy for HER-2/neu-positive cancers.

More Related Videos

A Simple and Efficient Approach to Construct Mutant Vaccinia Virus Vectors09:16

A Simple and Efficient Approach to Construct Mutant Vaccinia Virus Vectors

Published on: October 30, 2016

Related Concept Videos

Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
Mechanisms of Retrovirus-induced Cancers01:51

Mechanisms of Retrovirus-induced Cancers

Retroviruses are RNA viruses that have been shown to cause cancers in diverse species, including chickens, mice, cats, and monkeys. The RNA genomes of these viruses are first reverse-transcribed into single and then double-stranded DNA (dsDNA) copies. This dsDNA called proviral DNA then integrates into the host genome. Subsequently, the host cell transcribes the proviral DNA in concert with the chromosomal DNA. This leads to the production of viral RNA and proteins that assemble at the host...
Mechanisms of Retrovirus-induced Cancers01:51

Mechanisms of Retrovirus-induced Cancers

Retroviruses are RNA viruses that have been shown to cause cancers in diverse species, including chickens, mice, cats, and monkeys. The RNA genomes of these viruses are first reverse-transcribed into single and then double-stranded DNA (dsDNA) copies. This dsDNA called proviral DNA then integrates into the host genome. Subsequently, the host cell transcribes the proviral DNA in concert with the chromosomal DNA. This leads to the production of viral RNA and proteins that assemble at the host...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...